- Home
- ARWR vs BMRN Comparison
ARWR vs BMRN Comparison
Compare ARWR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | BMRN |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.4B |
| IPO Year | 2009 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ARWR | BMRN |
|---|---|---|
| Price | $77.64 | $57.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 18 |
| Target Price | $83.40 | ★ $88.22 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | $16,142,321.00 | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $15.02 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | ★ N/A | $97.67 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $14.30 | $49.26 |
| 52 Week High | $82.26 | $66.28 |
Technical Indicators
Market Signals| Indicator | ARWR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 56.42 | 61.54 |
| Support Level | $70.49 | $51.74 |
| Resistance Level | $82.26 | $56.91 |
| Average True Range (ATR) | 3.69 | 1.72 |
| MACD | -0.19 | 0.44 |
| Stochastic Oscillator | 66.36 | 98.01 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.